ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Regulatory news

EU · CHMP positive opinion: new indication

Trastuzumab deruxtecan (Enhertu)

Early breast cancer Enhertu as monotherapy is indicated for the adjuvant treatment of adult patients with resected HER2-positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2-targeted treatment (for biomarker-based patient selection, see section 4.2).

Conditional
CHMP opinion 17 Sept 2026 · Daiichi Sankyo Europe GmbH

Research

Oncology · Ann Oncol · 2026-03-02

Post hoc subgroup analysis of DESTINY-Breast06 (N=866, HR-positive HER2-low/-ultralow metastatic breast cancer): trastuzumab deruxtecan improved median PFS vs chemotherapy regardless of time to progression on prior ET+CDK4/6i (eg <6 months: 14.0 vs 6.5 months) or disease burden.

Secondary analysisn = 866
Curigliano et al. Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of disease

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.